Diffusion Tensor Imaging (DTI) analysis was performed in the multi-site
phase II trial of ibudilast in progressive multiple sclerosis. This study
extends that analysis to three pathways to examine DTI measures in 31
progressive MS patients on treatment and 31 patients on placebo. Probabilistic
tracking maps were generated. Mean pathway diffusion measures: longitudinal
diffusivity (LD) and transverse diffusivity (TD) are reported. We report here
that diffusion measures don’t significantly change over time in the treatment
group but we observe a significant change over time in the placebo group.